Prognostic outcome of intravenous thrombolysis with non-immunogenic staphylokinase in patients aged ≥ 60 years with acute ischemic stroke by THRIVE scale
Journal of Thrombosis and Thrombolysis · 2025
DOI: 10.1007/s11239-025-03212-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Thrombolysis, 2025. Verfasst von Nikolay A Shamalov und 9 weiteren Autor:innen. Beteiligte Einrichtung: Federal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency, Moscow, Russia. Hauptthemen laut MEDLINE: Ischemic Stroke, Thrombolytic Therapy, Metalloendopeptidases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Ministry of Science and Higher Education of the Russian Federation.
Themen: Schlaganfall
Abstract (Originalsprache)
This study aimed to assess the prognostic value of the THRIVE scale in patients aged ≥ 60 years with acute ischemic stroke (AIS) after intravenous thrombolysis with the non-immunogenic staphylokinase compared with alteplase. The post-hoc analysis of FRIDA trial results was performed and enrolled patients aged ≥ 60 years were divided into two groups in accordance with the modified Rankin scale (mRS) score on day 90: good-outcome (mRS 0-2) and poor-outcome (mRS 3-6) groups. The receiver operating characteristic (ROC) curves were compared using Delong test. For all-cause mortality on day 90 the predicted AUC value by the THRIVE scale was 0.8 (0.71-0.9) in the non-immunogenic staphylokinase group and 0.76 (0.66-0.87) in the alteplase group (p = 0.57). For poor outcome, AUC value was 0.73 (0.64-0.82) in the non-immunogenic staphylokinase group and 0.79 (0.71-0.87) in alteplase group (p = 0.36). Thus, our study confirmed the prognostic value of the THRIVE scale to predict the outcomes of the patients aged ≥ 60 years treated with the non-immunogenic staphylokinase.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Federal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency, Moscow, Russia.
- Belgorod State National Research University, Belgorod, Russia.
- National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia.
- Lomonosov Moscow State University, Moscow, Russia.
- Patrice Lumumba Peoples' Friendship University of Russia (RUDN), Moscow, Russia.
- Institute of Biomedical Chemistry, Moscow, Russia.
Förderung
- Ministry of Science and Higher Education of the Russian Federation
Zitieren
APA
Shamalov, N. A., Chefranova, Z. Y., Yarovaya, E. B., Kutsenko, V. A., Marskaya, N. A., Semenov, A. M., Semenov, M. P., Ivanov, S. V., Romashova, Y. A., & Markin, S. S. (2025). Prognostic outcome of intravenous thrombolysis with non-immunogenic staphylokinase in patients aged ≥ 60 years with acute ischemic stroke by THRIVE scale. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-025-03212-0
Vancouver
Shamalov NA, Chefranova ZY, Yarovaya EB, Kutsenko VA, Marskaya NA, Semenov AM, et al. Prognostic outcome of intravenous thrombolysis with non-immunogenic staphylokinase in patients aged ≥ 60 years with acute ischemic stroke by THRIVE scale. Journal of Thrombosis and Thrombolysis. 2025. doi:10.1007/s11239-025-03212-0
BibTeX
@article{Shamalov2025,
author = {Shamalov, Nikolay A and Chefranova, Zhanna Yu and Yarovaya, Elena B and Kutsenko, Vladimir A and Marskaya, Natalya A and Semenov, Andrey M and Semenov, Mikhail P and Ivanov, Sergey V and Romashova, Yulia A and Markin, Sergey S},
title = {Prognostic outcome of intravenous thrombolysis with non-immunogenic staphylokinase in patients aged ≥ 60 years with acute ischemic stroke by THRIVE scale},
journal = {Journal of Thrombosis and Thrombolysis},
year = {2025},
doi = {10.1007/s11239-025-03212-0}
}
EUVIMED